“We remain on track with our dose optimization studies for danuglipron, our oral GLP-1 receptor agonist candidate and look forward to discussing more about this in early 2025.”

In context

“going Phase II study evaluating safety and efficacy. We had a Phase II readout of ponsegromab, which is another in-house discovered and developed by us. We are encouraged by the potential for a breakthrough for patients with cancer cachexia, who lack treatment options for this life whitening wasting condition that currently has no FDA-approved treatments. The Phase II study met its primary endpoints change from baseline in body weight compared to placebo across all dose tests. And the highest dose of [indiscernible], sought improvements for baseline in appetite, cachexia symptoms, physical activity and muscle mass. Based on these positive results, we expect to advance to a registration-enabling study next year. Our Phase II study in patients with heart failure related cachexia is ongoing. We remain on track with our dose optimization studies for danuglipron, our oral GLP-1 receptor agonist candidate and look forward to discussing more about this in early 2025. In our broader obesity portfolio, we continue to advance our early-stage candidates, including our oral small module GIPR antagonist, which is advancing to Phase II in 2024 this year. And in additional, all once daily oral GLP-1 receptor agonist in Phase I. The highlights, I mentioned today across important therapeutic areas show how we have made meaningful advancements with our pipeline. As we announced earlier this year, Dr. Mikael Dolsten, Pfizer's Chief Scientific Officer, will depart from Pfizer after 15 years of leading Pfizer's research efforts. Our progress for selecting a successor is not quite advanced, and we look forward to announcing an update soon. Now I will turn to our commercial performance. And another one of our strategic priorities is maximizing the performance of our”